GBA Group Pharma

Your Challenges Require Smart Solutions

About

One of Europe’s largest and most experienced service providers

GBA Group Pharma is a member of the GBA Group and a unique service provider for the international pharmaceutical and biotech industry, with six locations across Austria and Germany. The well-known companies Pharmacelsus, GBA Pharma Labs, LKF Central Laboratory and ABF Pharmaceutical Services operate under the roof of GBA Group Pharma.

From early lead optimization and early preclinical stage to global clinical studies, we support clients throughout the entire lifecycle with our worldwide acting central laboratory, GMP depots, EU GMP manufacturing site for labeling and packaging and QP services, as well as late drug development and analytical services including import testing and QP batch release.

GBA Group Pharma is one of Europe’s largest and most experienced service providers for the pharmaceutical and biotech sector and has a total of 400 employees in Austria, Germany and the UK.

Latest News

6/1/2020

Expanded Range of COVID-19 Testing Methods for Clinical Trials Announced

Press Article

Laboratorium für Klinische Forschung, a member of GBA Group Pharma, is offering an analytical method for detecting SARS-CoV-2 from nasopharyngeal swabs. This has enabled the company to significantly expand its existing range of COVID-19 testing methods for clinical trials. Based on a Roche LightCycler 480 II, which uses the technique of real-time PCR (polymerase chain reaction), LKF can now perform numerous molecular biological applications (DNA or RNA analyses). The detection of the RNA of the SARS-CoV-2 virus is a prerequisite for the diagnosis of an acute infection with the new corona virus causing the disease COVID-19.

published in LABMATE on the 1st June 2020

Brexit Safe Haven

We at GBA Group Pharma are one of a few vendors in the area of QP release, import into Europe as well as batch release testing that can grant CTSM (clinical trial supply management) and commercial supply after Brexit without any implications on our clients.

New GMP facilities for CTSM and commercials in Vienna place the company in a unique position as EMA clearly states that GMP depots, QP release activities and GMP testing must be located in the EU. The growth in size and service offerings will make GBA Group Pharma one of only a few companies able to offer a Brexit Proof Solution to the pharmaceutical industry.

EMA specifies clear regulations for medicines manufactured in the EU. When UK leaves the EU, GBA Group Pharma will be one of the few service providers in the EU which can meet this criteria

Elisabeth Lackner, CEO ABF & GBA Group Pharma